BTIG Reiterates Buy Rating on Anavex Life Sciences (AVXL) After Management Confirms Filing is Going Ahead without Ph2/3 Data
Tweet Send to a Friend
BTIG analyst Yun Zhong reiterated a Buy rating and $35.00 price target on Anavex Life Sciences (NASDAQ: AVXL) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
